Baculoviral IAP repeat-containing protein 5 (BIRC5), Forkhead box protein M1 (FOXM1), and Bcl-2-like protein 1 (BCL2L1) (BIRC5/FOXM1/BCL2L1)

This target profile represents a triad of cross-reactive tumor-associated antigens (TAAs): Baculoviral IAP repeat-containing protein 5 (BIRC5/Survivin), Forkhead box protein M1 (FOXM1), and Bcl-2-like protein 1 (BCL2L1/Bcl-xL). BIRC5 is a member of the inhibitor of apoptosis (IAP) family that functions as a key regulator of mitosis and programmed cell death (UniProt O15392). FOXM1 is a proliferation-associated transcription factor essential for the execution of the mitotic program and DNA damage repair (UniProt Q08050). BCL2L1 is a potent anti-apoptotic protein within the Bcl-2 family that prevents mitochondrial outer membrane permeabilization (UniProt Q07817). These three proteins are frequently co-overexpressed in various aggressive malignancies, such as glioblastoma and adrenocortical carcinoma, while remaining largely absent in differentiated adult tissues, making them ideal targets for multi-antigen immunotherapy (PubMed: 32810104). Therapeutic approaches like the microbiome-derived peptide vaccine EO2401 leverage "OncoMimics"—peptides from gut bacteria that mimic these human TAAs—to trigger a robust cytotoxic T-cell response against tumor cells (Enterome, 2023; NCT04116658). By targeting multiple antigens simultaneously, these therapies aim to reduce the risk of tumor immune escape and address the inherent heterogeneity of solid tumors.

Other names

SurvivinFOXM1Bcl-xLBcl2-L1API4FKHL16TRIP13OncoMimicsBIRC5BCL2L1

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) responses through molecular mimicry or direct peptide presentation; direct inhibition of protein function by small molecules.